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Full details for both
flow cytometry panels
and gating strategiesT cells play a key role in adaptive immunity. Defects in specific T cell receptors or signaling
proteins can alter their frequency and activation status, which may be associated with immune
disease or cancer. Monitoring of T cell frequency and function in genetically modified mice or
murine models of disease is therefore of high interest. Here, we provide a detailed protocol to
analyze regulatory T cells, T cell activation, and cytokine production in thymus, spleen, or blood
via flow cytometry.Skordos et al., STAR Protocols
2, 100351
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T cells play a key role in adaptive immunity. Defects in specific T cell receptors or
signaling proteins can alter their frequency and activation status, which may be
associated with immune disease or cancer. Monitoring of T cell frequency and
function in genetically modified mice or murine models of disease is therefore
of high interest. Here, we provide a detailed protocol to analyze regulatory
T cells, T cell activation, and cytokine production in thymus, spleen, or blood
via flow cytometry.
For complete details on the use and execution of this protocol, please refer to
Demeyer et al. (2020).
BEFORE YOU BEGIN
Mice
Before starting with this protocol, ensure that you have sufficient amounts of age- and sex-matched
control and genetically modified mice from the appropriate mouse strain. We recommend using
mice older than 8-weeks for T cell studies (Jackson et al., 2017). To guarantee a pronounced statis-
tical significance, we suggest using a minimum amount of 5 animals per group.
Prepare flow cytometric panels
Timing: 0.5–1 h
1. Set up the flow panels to study T cells in thymus, spleen, and blood of mice and ensure that you
have sufficient amounts of flow cytometry antibodies for the number of samples you want to
analyze.
Prepare reagents
Timing: 1–4 h, can be done the days prior to the day of the protocol
2. Make sure you have all reagents mentioned under Materials and equipment.
Prepare materials for blood and lymphoid tissue collection / processing
Timing: 0.5–1 h, can be done the day prior to the day of the protocolSTAR Protocols 2, 100351, March 19, 2021 ª 2021 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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OPEN ACCESS Protocol3. Assure that you have all the necessary materials for blood and lymphoid tissue collection/pro-
cessing.
a. Prepare blood collection tubes by adding 50 mL EDTA (500 mM) in 1.5 mL Eppendorfs.
b. Prepare collection tubes for the spleen by adding 3 mL T cell culture medium in 15 mL tubes.
c. Preparecollection tubes for the thymusbyadding1mLTcell culturemedium in1.5mLEppendorfs.
d. Prepare 15 mL tubes containing 5 mL of ACK lysis buffer for blood samples.
e. Pre-label all the required 15 and 50 mL tubes needed to make single-cell suspensions.KEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-mouse CD3e PE-Cy5 (145-2C11) TONBO Biosciences Cat# 55-0031; RRID: AB_2621815
Anti-mouse CD4 APC-eFluor 780 (RM4-5) eBioscience Cat# 47-0042-82; RRID: AB_1272183
Anti-mouse CD4 BUV395 (GK1.5) BD Cat# 563790; RRID: AB_2738426
Anti-mouse CD8a PE-Cy7 (53-6.7) eBioscience Cat# 25-0081-82; RRID: AB_469584
Anti-mouse CD8a FITC (53-6.7) BD Cat# 553030; RRID: AB_394568
Anti-mouse CD16/32 purified
(Mouse BD FC Block)
BD Cat# 553142; RRID: AB_394657
Anti-mouse CD25 BUV395 (PC61) BD Cat# 564022; RRID: AB_2722574
Anti-mouse CD44 Alexa Fluor 700 eBioscience Cat# 12-0441-81; RRID: AB_465663
Anti-mouse CD44 PE (IM7) BioLegend Cat# 103012; RRID: AB_312963
Anti-mouse CD45R/B220 BUV496
(RA3-6B2)
BD Cat# 612950; RRID: AB_2722578
Anti-mouse CD62L PE (MEL-14) eBioscience Cat# 12-0621-82: RRID: AB_465721
Anti-mouse CD62L eFluor 450 (MEL-14) eBioscience Cat# 48-0621-80; RRID: AB_1963591
Anti-mouse CD120b BV421 (TR75-89) BD Cat# 564088; RRID: AB_2738585
Anti-mouse CD152 PE-eFluor
610 (UC10-4B9)
eBioscience Cat# 61-1522-82; RRID: AB_2574580
Anti-mouse FoxP3 APC (FJK-16s) eBioscience Cat# 17-5773-82; RRID: AB_469456
Anti-mouse IFN gamma PE-Cy7 (XMG1.2) eBioscience Cat# 25-7311-82; RRID: AB_469680
Anti-mouse IL-2 APC-Cy7 (JES6-5H4) BD Cat# 560547; RRID: AB_1727544
Anti-mouse IL-4 APC (11B11) eBioscience Cat# 17-7041-81; RRID: AB_469493
Anti-mouse IL-17 PerCP-Cyanine5.5 (eBio17B7) eBioscience Cat# 45-7177-80; RRID: AB_925754
Anti-mouse TNF Alexa Fluor 700 (MP6-XT22) BD Cat# 558000; RRID: AB_396980
Chemicals, peptides, and recombinant proteins
2-Mercaptoethanol (50 mM) Gibco Cat# 31350010
ACK lysis buffer Gibco Cat# A1049201
Brefeldin A Sigma-Aldrich Cat# B7651
13 D-PBS liquid w/o Ca and Mg Gibco Cat# 14190-094
Dimethyl sulfoxide Hybri-Max (DMSO) Sigma-Aldrich Cat# D2650
EDTA disodium salt dihydrate
99.0-101.0%, AnalaR NORMAPUR
ACS, Reag. Ph. Eur. analytical reagent
VWR Cat# 20302.293
Ethanol absolute, EMSURE ACS,
ISO, Reag. Ph. Eur. for analysis, Supelco
VWR Cat# 1.00983.1011
Fetal bovine serum Bodinco n/a
Ionomycin calcium salt (from
Streptomyces conglobatus)
Sigma-Aldrich Cat# 407952
L-Glutamine (200mM) Lonza Cat# BE17-605F
Penicillin-streptomycin solution stabilized Sigma-Aldrich Cat# P4333
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich Cat# P8139
RPMI 1640 w/o NaHCO3, w/ L-glutamine Gibco Cat# 52400-025
Sodium pyruvate solution (100 mM) Sigma-Aldrich Cat# S8636
Trypan blue Sigma-Aldrich Cat# 1.11732
(Continued on next page)
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Critical commercial assays
BD Horizon Brilliant Stain Buffer BD Cat# 566349
Fixable Viability Dye eFluor 506 eBioscience Cat# 65-0866-14




UltraComp eBeads Compensation Beads Invitrogen Cat# 01-2222-42
Experimental models: organisms/strains
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Other
15 mL centrifuge tubes Corning Cat# 430791
50 mL centrifuge tubes Corning Cat# CLS430897
96-well polypropylene storage microplates Nunc Cat# 249944
BD LSRFortessa 5 laser flow cytometer BD n/a
Cell culture CO2 incubator Thermo Scientific Cat# 3311
Cell strainers 70 mm white Falcon Cat# 352350
Centrifuge Thermo Scientific Multifuge 3SR+
Clustertubes 1.2 mL for FACS Costar Cat# COS4401
Curved forceps (Dumont #7b
Medical Forceps-Inox Standard Tip)
Fine science tools Cat# 11270-20
Gosselin Petri Dish 100 3 15 mm,
3 Vents, Aseptic
Corning Cat# SB93-101
Injection needles, 26G 3 1/2 inch HSW FINE-JECT n/a
Cell counting chamber without
clamps, dark lined, Bürker
MARIENFELD Cat# 0640210
SafeSeal tube 1.5 mL SARSTEDT AG & Co. KG Cat# 72.706
Stericup Quick Release-GP sterile
vacuum filtration system
Millipore Cat# S2GPU05RE
Straight forceps with blunt
points L120 mm
Surpodo Cat# A11623
Student Fine scissors straight 11.5 cm Fine Science Tools Cat# 91460-11
Syringe 2 mL (3 mL) luer Norm-Ject Cat# 4020-000V0
Tissue culture plate, 48 well, flat
bottom with low evaporation lid
Falcon Cat# 353078
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OPEN ACCESSProtocolMATERIALS AND EQUIPMENT
T cell culture medium
To make 500 mL of T cell culture medium, dissolve 5 mL 200 mM L-glutamine (final concentration
2 mM), 5 mL Penicillin-streptomycin, 1 mL 50 mM 2-mercaptoethanol (final concentration
0.1 mM), 1 mL 100 mM sodium pyruvate solution (final concentration 0.2 mM) and 50 mL of heat in-
activated Fetal Bovine Serum (final concentration 10%) in 438 mL of RPMI 1640 and filter the culture
media using a GP sterile vacuum filtration system. Store at 4C for up to 1 month.Fixable viability dye
Prepare a working solution of the Fixable Viability Dye eFluor 506 by adding 450 mL of 13 D-PBS to
the vial (final concentration 1:10). Store at 80C in 50 mL aliquots for up to 6 months.STAR Protocols 2, 100351, March 19, 2021 3
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OPEN ACCESS ProtocolAzide
To make 10 mL of Azide, dissolve 2 g Azide in 10 mL of ultra-pure water (final concentration 20% w/
v). Store at 4C for up to 1 year.
EDTA (500 mM)
To make 500 mM EDTA, dissolve 186.12 g EDTA disodium dihydrate in 1,000 mL ultra-pure water
and adjust the buffer’s pH to 8 by adding 5 M NaOH. Store at 4C for up to 6 months.
FACS buffer
To prepare 1 L of FACS buffer, dissolve 1 g BSA (final concentration 0.1%), 4 mL 500 mM EDTA (final
concentration 2mM) and 1mL 20% Azide (final concentration 0.02%) in 900mL 13D-PBS and adjust
the volume to 1,000 mL with 13 D-PBS. Store at 4C for up to 6 months.
Fc blocking buffer
To make Fc blocking buffer for 1 sample, add 1 mL of anti-CD16/32 antibody (Key resources table)
into 99 mL 13 D-PBS. ALWAYS prepare freshly. Store at 4C for up to 24 h.
PMA
Prepare a PMA stock solution by dissolving 5 mg PMA in 5 mL DMSO (final concentration 1 mg/mL)
under aseptic conditions. Store at 20C in 50 mL aliquots for up to 1 year.
Ionomycin
Prepare an ionomycin stock solution by dissolving 1 mg ionomycin in 1.338 mL 13 D-PBS (final con-
centration 747 mg/mL) under aseptic conditions. Store at 4C in 20 mL aliquots for up to 1 year.
Brefeldin A (BFA)
Prepare a BFA stock solution by adding 250 mL of DMSO to the vial (final concentration 20 mg/mL)
under aseptic conditions. Store at 20C in 15 mL aliquots for up to 1 year.
70% Ethanol
To make 500 mL 70% ethanol, mix 350 mL of absolute ethanol with 150 mL of tap water. Store at
20C–25C.
0.1% Trypan blue
Prepare a 0.1% trypan blue stock solution by dissolving 50 mg trypan blue powder in 50 mL 13 D-




This step contains information on collecting blood, thymus, and spleen from mice to study T cells.
1. Euthanize the mouse by CO2 inhalation.
2. Place the animal on its back on a dissection mat, pin the paws on the mat and wet the fur by spray-
ing with 70% ethanol.
3. Make an incision in the abdominal area above the urethral opening, without penetrating the
abdominal wall, and extend the incision until the neck with a pair of straight scissors. Extent
also the incision to the hind legs and pin the loose skin on the mat.
4. To study circulating T cells, collect blood by cardiac puncture. Penetrate the diaphragm from the
xiphoid with a pair of straight scissors and delicately cut the ribs on each side up to the clavicle.
Then lift the ribs with a pair of straight forceps with blunt points, pin them to the mat and insert a4 STAR Protocols 2, 100351, March 19, 2021
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OPEN ACCESSProtocol26G 3 1/2 inch needle attached to a 1 mL syringe in the lower left ventricle part of the heart to
collect up to 500 mL of blood. Finally, transfer the blood to a 1.5 mL blood collection tube con-
taining 50 mL EDTA (500 mM), invert the tube 5 times, to avoid blood clotting, and store the sam-
ple on ice.
Note: For long-term in vivomonitoring of lymphocytes inmice, one can obtain circulating lym-
phocytes via submandibular vein puncture instead of cardiac puncture.
5. Next, isolate the thymus by disconnecting the connective tissue surrounding the thymus and
gently remove the thymic lobes using a pair of curved forceps. Place the thymus into a 1.5 mL
collection tube containing 1 mL of T cell culture medium and store it on ice.
CRITICAL: While cutting the ribs and during the cardiac puncture avoid cutting thethoracic blood vessels, since this will lead to blood leakage and contamination of the
thoracic cavity with circulating lymphocytes. If there is blood leakage, the thymus needs
to be rinsed in 13 D-PBS before placing the thymus in the collection tube.6. Finally, isolate the spleen bymaking a 1.5 cm incision in the peritoneum and gently pull the spleen
to the surface. Clean up the spleen by removing the pancreatic tissue attached to the spleen with
a pair of straight scissors and transfer the spleen with a pair of straight, blunt pointed forceps to a
15 mL collection tube containing 3 mL of T cell culture medium.
Processing of samples
Timing: 1.5–2 h
This step details how to prepare single-cell suspensions from spleen, thymus, and blood. Online one




a. Pour the spleen with T cell culture medium into a 10 mm bacterial Petri dish.CRITICAL: For maintaining aseptic conditions, work under a fume hood.b. While holding the spleen in the Petri dish with a pair of straight forceps with blunt points, flush
out the splenocytes by injecting T cell culture medium (collected from the Petri dish) in the
spleen with a 3 mL syringe (26G 3 1/2 inch needle).
c. Smash the spleen by using the plunger of the 3 mL syringe and a pair of straight blunt pointed
forceps.
d. Transfer the medium containing the smashed spleen to a 70 mm cell strainer on top of a 50 mL
tube.
e. Use the plunger again to smash the remaining spleen pieces on the cell strainer.
f. Rinse the Petri dish with 3 mL of T cell culture medium to get all remaining spleen pieces and
transfer them to the 70 mm cell strainer.
g. Smash the remaining spleen pieces.
h. Rinse the 70 mm cell strainer with 3 mL of T cell culture medium, discard the cell strainer, and
place the sample immediately on ice.
i. Centrifuge the sample at 400 3 g for 4 min at 4C.
Note: To decrease experimental time if you are working alone, we advise to start preparing
thymic single-cell suspensions during the centrifugation steps of splenocytes isolation.STAR Protocols 2, 100351, March 19, 2021 5
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OPEN ACCESS Protocolj. Discard supernatant using a vacuum pump and add 2mL of ACK lysis buffer to the 50mL tube,
close the tube, and resuspend the splenocytes by pulse vortexing. Incubate for 3 min at 20C–
25C.
k. Add 6 mL of T cell culture medium to stop the lysis of red blood cells, place the 50 mL tube on
ice and centrifuge the sample at 400 3 g for 4 min at 4C.
l. Discard the supernatant and resuspend the splenocytes with 3 mL of T cell culture medium
and keep on ice until stimulation/staining.
m. Count splenocytes with a counting chamber (1:100 dilution in 0.1% trypan blue).
8. Thymus
a. Transfer the thymus to a 70 mm cell strainer on top of a 50 mL tube using a clean pair of straight
forceps with blunt points.
b. Smash the thymus on the cell strainer using the plunger of a new 3mL syringe and rinse the cell
strainer with 3 mL of T cell culture medium.
c. Smash the remaining thymus pieces, rinse the cell strainer oncemore with 3 mL of T cell culture
medium and place the sample on ice.
d. Centrifuge the sample at 400 3 g for 4 min at 4C.
e. Discard the supernatant and resuspend the thymocytes with 3 mL of T cell culture medium and
keep on ice until staining.
f. Count thymocytes with a counting chamber (1:100 dilution in 0.1% trypan blue).
9. Blood
a. Transfer the blood sample to a 15 mL tube containing 5 mL of ACK lysis buffer, close tube,
vortex shortly (5 s) and incubate at RT for 3 min.
b. Put the tubes back on ice and add 8mL cold T cell culture medium to stop red blood cells lysis.
c. Centrifuge the sample at 400 3 g for 4 min at 4C.
d. Discard the supernatant and resuspend the cells with 200 mL of T cell culture medium. Keep on
ice until staining.
Note:Mostof the time, this experiment is labor-intensive.Therefore,we recommendhavingR two
peopleworking together to prepare single-cell suspensions (preferably one researcher per tissue).
Note: Instead of T cell culture medium, one can use 13D-PBS for the rinsing steps and to stop
the ACK lysis step.
Stimulation of splenocytes for intracellular cytokine staining (ICS)
Timing: 4.5 h
This step details how to stimulate splenic single-cell suspensions with PMA/ionomycin/BFA to assess
the intracellular cytokine production of T cells.
10. Stimulation of splenocytes6
a. Prepare a 103 mix of PMA/ionomycin/BFA by adding 0.5 mL PMA, 6.66 mL ionomycin and
5 mL BFA to 987.84 mL T cell culture medium (concentration 500 ng/mL, 5,000 ng/mL and
100 mg/mL, respectively). The volume needed is 20 mL/sample.
b. Prepare a 103mix with only BFA by adding 0.5 mL BFA to 99.5 mL T cell culture medium (con-
centration 10 mg/mL). The volume needed is 20 mL/sample.
Note: After use, immediately place the stock solution of ionomycin at 4C and the stock solu-
tions of PMA and BFA at 20C.
c. Transfer 1.5million splenocytes to a well of a 48-well flat-bottom culture plate. Adjust the vol-
ume in the well at 180 mL by adding T cell culture medium.STAR Protocols 2, 100351, March 19, 2021
Table 1. Antibody mix for the extracellular staining of splenic T cells
Fluorophore Marker Final dilution Volume for 1 sample




PE-Cy5 CD3e 1/200 0.5 mL
APC-eFluor 780 CD4 1/200 0.5 mL
PE-Cy7 CD8a 1/600 0.16 mL
BUV395 CD25 1/100 1 mL
Alexa Fluor 700 CD44 1/100 1 mL
PE CD62L 1/200 0.5 mL
BV421 CD120b 1/100 1 mL
Sum of antibodies 6.16 mL
13 D-PBS 43.84 mL
BD Horizon Brilliant Stain Buffer 1/2 50 mL
Final staining volume 100 mL
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OPEN ACCESSProtocolNote: The flow cytometry analysis requires additional samples for unstained, single-stained
cell, and negative cell controls, as described in step 10c. You need one negative cell control,
one unstained control and ten single-stained cell control samples (see Tables 7 and 8).
d. Add 20 mL of the PMA/ionomycin/BFA mix (final concentration for T cell stimulation is 50 ng/
mL, 500 ng/mL, 10 mg/mL, respectively) to all samples, with the exception of the negative
control sample to which 20 mL of the BFA only mix (final concentration 10 mg/mL) is added.
e. Place the culture plate in a 37C, 5% CO2 cell culture incubator for 4 h.
f. After 4 h, place the culture plate on ice until intracellular cytokine staining.
CRITICAL: For maintaining aseptic conditions, work under a fume hood.Flow cytometry antibody staining of T cells in blood, thymus, and spleen
Timing: 5–6 h
This step details the staining of splenic, thymic and blood single-cell suspensions with fluorophore-
conjugated anti-mouse antibodies (see Tables 1, 2, 3, 4, 5, 6, 7, and 8) to study T cells in spleen,
thymus, and blood. Single-stained cell control samples are needed to set the PMT voltage for
each parameter and single-stained eBeads (UltraComp eBeads Compensation beads) controls are
needed for compensation, except for the Fixable Viability Dye for which cells will be used. Figure 1
shows an example of a plate layout to stain for T cell activation and Treg cell functionality in ten
mouse spleens.
CRITICAL: All antibodies and buffers should be kept on ice while preparing antibodymixes.Note: Tables 1, 2, 3, 4, 5, 6, 7, and 8 provide antibody volumes to stain one sample (final stain-
ing volume 100 mL). To stain more than one sample, prepare an excess of two samples by
multiplying the indicated volumes by the number of samples + 2.
Note: To aid with the discrimination of certain gates, one can set up fluorescent minus one
(FMO) controls, where the marker of interest is omitted from the staining mix. In this protocol
we recommend the use of FMO controls for CD152 (CTLA4) and the CD120b (TNFR2) anti-
bodies to aid the gating for CTLA4+ and TNFR2+ Treg cells. However, the use of FMO controls
can be extended to other markers, depending on the experience of the researcher.STAR Protocols 2, 100351, March 19, 2021 7
Table 2. Antibody mix for the intracellular staining of splenic T cells
Fluorophore Marker Final dilution Volume for 1 sample
PE-eFluor 610 CD152 1/50 2 mL
APC FoxP3 1/50 2 mL
Sum of antibodies 4 mL
13 Permeabilization Buffer from FoxP3/Transcription
Factor Staining Buffer Set
96 mL
Final staining volume 100 mL
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a. eBeads mix: add 7 drops from the stock vial to a 15 mL tube containing 7 mL 13 D-PBS (1
drop/mL). Vortex thoroughly and keep on ice. 200 mL of eBeads mix is required per anti-
mouse antibody.
b. Antibodymixes for the extracellular staining of cells with fluorophore-conjugated anti-mouse
antibodies in the appropriately labeled 1.5 mL Eppendorfs, by following the volumes indi-
cated in Tables 1, 3, 5, and 7.
i. Start by adding 13 D-PBS to a 1.5 mL Eppendorf.
Note: The volume of 13 D-PBS for one sample is based on the following formula: volume of
13 D-PBS = 100 mL (final staining volume/sample) - sum of antibodies - volume of BD Horizon








STii. Continue by adding BD Horizon Brilliant Stain Buffer (at a dilution of 1/2 of the final stain-
ing volume).CRITICAL: BD Horizon Brilliant Stain Buffer is required when more than one BD HorizonBrilliant dye-conjugated antibody is used in the same flow panel to prevent the non-spe-
cific polymer interactions which can lead to data appearing under-compensated. In this
experiment, BD Horizon Brilliant Stain Buffer is used only in the antibody mixes of Tables
1 and 7.iii. Continue by adding fluorophore-conjugated anti-mouse antibodies and the Fixable
Viability Dye.
iv. Once finished, vortex for 5 s.
v. Store mixes in the fridge at 4C.Note: The antibody mixes can be made the day before, but the Fixable Viability Dye has to be
added just before adding the staining mix to the samples.
Alternatives: We use Fixable Viability Dye eFluor 506 because its emission spectrum is
compatible with our antibody staining panels. Alternatives, with similar emission properties,
are the Zombie Aqua Fixable Viability Kit from BioLegend (cat# 23101) and the LIVE/DEAD
Fixable Aqua Dead Cell Stain Kit by Invitrogen (cat# L34957). For the panel described inAntibody mix for the extracellular staining of thymic T cells
ore Marker Final dilution Volume for 1 sample
06 Fixable Viability Dye 1/200 0.5 mL
CD16/32 (Mouse BD Fc Block) 1/100 1 mL
uor 780 CD4 1/200 0.5 mL
CD8a 1/600 0.16 mL
ntibodies 2.16 mL
S 97.84 mL
ining volume 100 mL
AR Protocols 2, 100351, March 19, 2021
Table 4. Antibody mix for the intracellular staining of thymic T cells
Fluorophore Marker Final dilution Volume for 1 sample
APC FoxP3 1/50 2 mL
Sum of antibodies 2 mL
13 Permeabilization Buffer from FoxP3/Transcription
Factor Staining Buffer Set
98 mL













OPEN ACCESSProtocolTables 1 and 2, the LIVE/DEAD Fixable Green Dead Cell Stain Kit by Invitrogen (cat# L23101),
with different emission properties, can be used instead of Fixable Viability Dye eFluor 506.
These alternative viability dyes have not been tested and need further optimization.
CRITICAL: Since this experiment is labor-intensive, we recommend starting with the stain-ing of T cells in splenic, thymic and blood single-cell suspensions during the 4 h incubation
period of PMA/ionomycin/BFA-stimulated splenocytes.CRITICAL: Since some surface markers like CD62L are temperature sensitive, always keepthe 96-well v-bottom polypropylene plate on ice during the staining procedure and use a
centrifuge set at 4C.CRITICAL: All incubation steps should be done in the dark.
12. Staining for T cell activation and Treg cell functionality in the spleen of mice (see Figure 1 for a








ala. Transfer 1.5 million splenocytes into a well of a 96-well polypropylene v-bottom plate. Keep
the plate on ice.
b. Add an unstained cell control and 10 single-stained cell controls by transferring 1.5 million
splenocytes into 11 wells of the 96-well v-bottom plate.
Note: For the CD152 FMO and the CD120b FMO you need two additional wells with 1.5
million cells.
c. Heat-kill 1.5 million splenocytes for 1 min at 95C to generate a positive cell control for dead
cells.
d. Place heat-killed cells on ice for 1 min. Mix heat-killed cells with 1.5 million splenocytes of a
single-stained cell control sample. Use this sample as a single-stained cell control for the
Fixable Viability Dye.
e. Centrifuge the plate at 400 3 g for 4 min at 4C.
f. Discard the supernatant and resuspend cell pellets with 200 mL 13 D-PBS.
g. Centrifuge the plate at 400 3 g for 4 min at 4C.e 5. Antibody mix for the extracellular staining of T cells in the blood of mice
rophore Marker Final dilution Volume for 1 sample
r 506 Fixable Viability Dye 1/200 0.5 mL
CD16/32 (Mouse BD Fc Block) 1/100 1 mL
y5 CD3e 1/200 0.5 mL
-eFluor 780 CD4 1/200 0.5 mL
y7 CD8a 1/200 0.5 mL
a Fluor 700 CD44 1/200 0.5 mL
r 450 CD62L 1/200 0.5 mL
of antibodies 4 mL
-PBS 96 mL
staining volume 100 mL
STAR Protocols 2, 100351, March 19, 2021 9
Table 6. Antibody mix for the intracellular staining of T cells in the blood of mice
Fluorophore Marker Final dilution Volume for 1 sample
APC FoxP3 1/50 2 mL
Sum of antibodies 2 mL
13 Permeabilization Buffer from FoxP3/Transcription
Factor Staining Buffer Set
98 mL
















Protocolh. Discard the supernatant and resuspend cell pellets with 100 mL of extracellular staining anti-
body mix (see Table 1).
Note: Resuspend the CD152 FMO control in 100 mL of antibody mix for the extracellular
staining. Be aware, do not add anti-CD120b antibody in the extracellular staining antibody
mix for the CD120b FMO.
i. Resuspend unstained and single-stained cell controls with 100 mL of Fc blocking buffer (see
Materials and equipment) and add x mL of the relevant extracellular staining antibody to the
proper sample. Do not add antibody to the single-stained cell controls used for the detec-
tion of intracellular FoxP3 and CD152.
Note: In this case x mL is calculated based on the antibody’s final dilution, as indicated in
Table 1.
j. Add 200 mL of eBeads mix to ten wells of the 96-well v-bottom plate and add 0.5 mL of the
corresponding extracellular antibody, except for Alexa Fluor 700 and for APC-eFluor780:
1 mL and for PE, PE-tandem, and BV dyes: 0.2 mL.
Note: In this protocol, we use eBeads as compensation controls. We are aware that some labs
prefer single-stained cell for compensation controls in multicolor flow cytometry experiments.
However, for proper compensation one needs a distinct negative and positive population.
This will be challenging for markers expressed on a low number of cells, such as FoxP3 and
some intracellular cytokines. Therefore, we use eBeads that have a robust signal regardless of
the fluorophore-conjugated antibody that is bound. These eBeads consist of two populations
of beads: one that captures any mouse, rat, or hamster antibody and one that does not react
with antibodies. Adding a fluorophore-conjugated antibody will result in a negative and positive
peak, generating a bimodal distribution that can be used to perform compensation. Most of the
fluorophore-conjugated antibodies produce an optimal bimodal distribution at average concen-
trations. However, we have determined that for very bright fluorophores, such as PE, PE-tandem,
and BV dyes, less antibody should be used to keep the positive peak on scale. In contrast, wee 7. Antibody mix for the extracellular staining of PMA/ionomycin-stimulated splenic T cells
rophore Marker Final dilution Volume for 1 sample
r 506 Fixable Viability Dye 1/200 0.5 mL
CD16/32 (Mouse BD Fc Block) 1/100 1 mL
y5 CD3e 1/200 0.5 mL
395 CD4 1/200 0.5 mL
CD8a 1/200 0.5 mL
CD44 1/200 0.5 mL
496 CD45R/B220 1/400 0.25 mL
of antibodies 3.75 mL
-PBS 46.25 mL
orizon Brilliant Stain Buffer 1/2 50 mL
staining volume 100 mL
STAR Protocols 2, 100351, March 19, 2021
Table 8. Antibody mix for the intracellular staining of PMA/ionomycin-stimulated splenic T cells
Fluorophore Marker Final dilution Volume for 1 sample
PE-Cy7 IFN-g 1/160 0.63 mL
APC-Cy7 IL-2 1/200 0.5 mL
APC IL-4 1/100 1 mL
PerCP-Cyanine5.5 IL-17 1/160 0.63 mL
Alexa Fluor 700 TNF 1/100 1 mL
Sum of antibodies 3.76 mL
13 Permeabilization Buffer from BD Cytofix/Cytoperm kit 96.24 mL






OPEN ACCESSProtocolhave observed that for dim fluorophores, such as AF700, APC-Cy7, and APC-eFluor780, more
antibody is needed to achieve an optimal separation of the two peaks.
CRITICAL: Since eBeads precipitate rapidly, vortex eBeads mix thoroughly while addingthem to the 96-well v-bottom plate.k. Mix samples and eBeads by pipetting up and down and incubate on ice for 20 min in the
dark.
Note: During the incubation of samples with the antibody mix for extracellular staining, pre-
pare all required buffers to detect intracellular FoxP3 and CTLA4 expression in T cells, asre 1. Layout of a 96-well v-bottom plate setup for the staining of splenic T cell activation and Treg cell functionality of ten mice
nocytes are stained with the antibody mix for the extracellular staining and the intracellular staining as indicated in Tables 1 and 2 and described in
12, single-stained cell controls and eBeads compensation controls are stained with the indicated fluorophore-conjugated anti-mouse antibodies,
d on Tables 1 and 2. FMO, fluorescence minus one; FVD, fixable viability dye.









l. Add 100 mL 13 D-PBS to each sample, beads excluded, and centrifuge at 400 3 g for 4 min
at 4C.
m. Discard the supernatant and resuspend samples and eBeads with 100 mL fixation buffer.
n. Incubate samples on ice for 30 min in the dark.
o. Prepare the antibody mix for the intracellular staining (see Table 2) in an appropriately
labeled 1.5 mL Eppendorf and store in the fridge at 4C.
i. Start by adding 13 Permeabilization buffer.
ii. Continue by adding fluorophore-conjugated anti-mouse antibodies.
p. Centrifuge plate at 400 3 g for 4 min at 4C.
q. Discard the supernatant and resuspend cell pellets with 100 mL of intracellular staining anti-
body mix.
Note: Resuspend the CD120b FMO control in 100 mL of antibody mix for intracellular stain-
ing. Be aware, do not add anti-CD152 antibody in the intracellular staining antibody mix for
the CD152 FMO.
r. Resuspend unstained and single-stained cell controls with 100 mL 13 Permeabilization
buffer and add x mL of the relevant intracellular staining antibody to the proper sample.
Note: In this case x mL is calculated based on the antibody’s final dilution, as indicated in
Table 2.
s. Resuspend eBeads with 200 mL 13 Permeabilization buffer and add 0.5 mL of the corre-
sponding intracellular antibody to the beads, except for PE-tandem dyes: 0.2 mL.
t. Incubate samples on ice for 30 min in the dark.
u. Add 100 mL 13 Permeabilization buffer to each sample (not to the eBeads) and centrifuge at
400 3 g for 4 min at 4C.
v. Discard the supernatant and resuspend cell pellets and eBeads with 200 mL FACS buffer (see
Materials and equipment).
w. Transfer samples to pre-labeled 1.2 mL FACS tubes and store samples in the fridge at 4C
until detection.
Pause point: Since the cells are fixed, one can collect the data the following day.13. Staining of T cells and Treg cells in thymic and blood single-cell suspensionsa. Transfer 1–1.5 million thymocytes and 100 mL of the blood single-cell suspension containing
 0.2–1 million white blood cells into two distinct 96-well polypropylene v-bottom plates
(pre-labeled as thymus and blood plate). Keep both plates on ice.
b. Set up an unstained cell control and four single-stained cell controls by transferring 1.5
million thymocytes to the thymus-labeled 96-well v-bottom plate.
c. Set up an unstained cell control and seven single-stained cell controls by transferring 50 mL of
the blood single-cell suspension (a pool of the blood samples can be used) to the blood-
labeled 96-well v-bottom plate.
d. Set up single-stained cell controls for the Fixable Viability Dye (1:1mix of alive and heat-killed
cells) in both plates as described in steps 12c and d.STAR Protocols 2, 100351, March 19, 2021
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OPEN ACCESSProtocole. Continue with the extracellular and intracellular antibody staining of thymocytes and white
blood cells by following the previously described steps 12e–w. Always refer to Tables 3
and 6 for the appropriate antibody mix for intracellular staining.
Pause point: Since the cells are fixed, one can collect the data the following day.
14. Intracellular cytokine staining of PMA/ionomycin/BFA-stimulated splenic T cellsa. Transfer all samples from the 48-well flat-bottom culture plate to a 96-well polypropylene v-
bottom plate and keep the plate on ice.
Note: To detach all splenocytes from the bottom of the 48-well culture plate and increase cell
yield, loosen the cells by pipetting up and down a couple of times (clockwise).
b. Generate a single-stained cell control for the Fixable Viability Dye by heat-killing 100 mL of a
single-stained cell control sample as described in steps 12c and d.
c. Centrifuge the plate at 400 3 g for 4 min at 4C.
d. Discard the supernatant, resuspend cell pellets with 200 mL 13 D-PBS and follow the
same procedure of extracellular staining with antibodies as described in steps 12g–l.
Always refer to Table 7 for the appropriate extracellular antibody mix for the staining
of cells.
Note: During the incubation of samples with the antibody mix for extracellular staining,
prepare all required buffers to detect intracellular cytokine production in T cells, as
described in the datasheet of the BD Cytofix/Cytoperm Fixation/Permeabilization Solu-
tion Kit (https://www.bdbiosciences.com/ds/pm/others/554714_554715_555028_Book_
Website.pdf).
e. Discard the supernatant and resuspend samples and eBeads with 100 mL fixation buffer.
f. Incubate samples on ice for 30 min in the dark.
g. Prepare the intracellular cytokine antibody staining as described in step 12o and store in the
fridge at 4C (see Table 8).
h. Centrifuge plate at 400 3 g for 4 min at 4C.
i. Discard the supernatant and resuspend non- and PMA/ionomycin-stimulated splenocytes
with 100 mL of intracellular staining antibody mix.
j. Resuspend unstained and single-stained cell controls with 100 mL 13 Permeabilization
buffer and add x mL of the relevant intracellular staining antibody to the proper sample.
Note: In this case x mL is calculated based on the antibody’s final dilution, as indicated in
Table 8.
k. Resuspend eBeads with 200 mL 13 Permeabilization buffer and add 0.5 mL of the corre-
sponding intracellular antibody to the beads, except for Alexa Fluor 700 and APC-
eFluor780: 1 mL and for PE, PE-tandem, and BV dyes: 0.2 mL.
l. Incubate samples on ice for 30 min in the dark.
m. Add 100 mL 13 Permeabilization buffer to each sample (not to the eBeads) and centrifuge at
400 3 g for 4 min at 4C.
n. Discard the supernatant and resuspend samples and eBeads with 200 mL FACS buffer (see
Materials and equipment).
o. Transfer samples in pre-labeled 1.2 mL FACS tubes and store samples in the fridge at 4C
until detection.
Pause point: Since the cells are fixed, one can collect the data the following day.STAR Protocols 2, 100351, March 19, 2021 13
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Timing: 3–4 h
This step details how to collect flow data using a five laser BD LSRFortessa cytometer and analyze
them using the FlowJo software.
Alternatives: The staining of T cells and Tregs in thymus and blood (Tables 3, 4, 5, and 6) can
also be acquired using a three laser BD LSR II cytometer or a three or four laser BD Fortessa
cytometer.
15. Acquire data with a BD LSRFortessa 5 laser flow cytometer within 24 h after staining at a flow rate
of 8000 events/s or less. Use unstained and single-stained cell controls to set suitable PMT volt-
ages. For the FSC and SSC, voltages are set so that the cells can be discriminated from the
debris, which should be present in the lower left of a FSC-A versus SSC-A plot (see Figures 2,
3, 4, and 5). For the other parameters the CS&T baseline target voltages are a good starting
point to set PMT voltages. If a positive population of a single-stained cell control is not on scale,
lower the PMT voltage to have the positive population on scale. For auto-compensation, use the
eBeads control samples and the heat-killed cell sample stained with Fixable Viability Dye eFluor
506. Once the PMT voltages are set and the auto-compensation is done, acquire at least 0.5
million living cells per tube.
Note: If the researcher is not familiar with setting up PMT voltages and performing auto-
compensation, we advise to get assistance from a more experienced researcher.
16. The acquired data can be analyzed with FlowJo software using linear scales for FSC-A, SSC-A
and FCS-H, and biexponential scales for the other markers.EXPECTED OUTCOMES
This protocol describes gating strategies to study T cells in mouse thymus, spleen, and blood. We
defined the different T cell populations based on extracellular and intracellular markers.
For all panels we first create a cell gate based on SSC-A and FSC-A parameters. We continue by
gating single cells by using the FSC-H and FSC-A parameters. Next, we use eFluor 506 Fixable
Viability Dye to separate dead from alive cells (Figures 2, 3, 4, and 5). To distinguish CD4CD8
(DN), CD4+CD8+ (DP) and CD4+CD8 or CD4CD8+ (SP) thymocytes, we look at CD4 and CD8a
expression on living cells (Figure 3). We did not include a CD3e antibody, since not all DN thy-
mocytes express CD3e on their surface and gating for CD3e prior to CD4 and CD8a gating
would result in loss of some DN thymocytes. On the living cell population, we can also gate
for T cells by using an anti-CD3e antibody (Figures 2 and 4) or T and B cells by using anti-
CD3e and anti-CD45R/B220 antibodies (Figure 5). T cells are further divided in CD4+ and
CD8+ T cell populations based on the expression of CD4 and CD8a, respectively (Figures 2,
4, and 5). To define the activation status of splenic and circulating CD4+ T and CD8+ T cells,
we use anti-CD44 and anti-CD62L antibodies, resulting in plots with CD44CD62L+ naive,
CD44+CD62L effector memory (TEM) and CD44+CD62L+ central memory (TCM) cells (Figures
2 and 4).
Thymic and circulating Treg cells are defined as FoxP3+CD4+ T cells (Figures 3 and 4), while splenic
Treg cells are also more specifically defined as FoxP3+CD25+CD4+ T cells (Figure 2). The splenic
FoxP3+ Treg cells are then further divided in CD44loCD62Lhi naive central Treg cells (cTregs) and
CD44hiCD62Llo effector Treg cells (eTregs) (Di Pilato et al., 2019; Yang et al., 2019). Finally, with
the help of FMO controls and the CTLA4 expression on CD4+ T cells, we can gate for the expression14 STAR Protocols 2, 100351, March 19, 2021
Figure 2. Gating strategy for T cell activation in spleen
CD4+ and CD8+ naive (CD44CD62L+), TEM (CD44+CD62L) and TCM (CD44+CD62L+) cells, CTLA4+CD4+ T cells, total Treg cells (FoxP3+) and
CD25+FoxP3+ Treg cells, Treg functionality markers (TNFR2+ or CTLA4+), cTregs (CD44loCD62Lhi), and eTregs (CD44hiCD62Llo).
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OPEN ACCESSProtocolof TNFR2 (CD120b) and CTLA4 (CD152), which are functionality markers for FoxP3+CD4+ Treg cells
(Figure 2) (Chen et al., 2008; Klocke et al, 2017).
In addition, we developed a gating strategy to study T helper and cytotoxic T cell populations inmouse
spleen, based on the intracellular expression of cytokines (Figure 5). PMA/ionomycin/BFA-stimulatedSTAR Protocols 2, 100351, March 19, 2021 15
Figure 3. Gating strategy for CD4CD8 (DN), CD4+CD8+ (DP), CD4+CD8 (SP), CD4CD8+ (SP) thymocytes, and FoxP3+CD4+CD8 thymic Tregs
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OPEN ACCESS Protocolcells will produce cytokines, but these cytokines cannot be secreted since BFA is used. By using the
BFA only negative control, we can determine PMA/ionomycin-induced IFN-g (Th1), IL-4 (Th2),
IL-17 (Th17), IL-2 and TNF producing CD4+ T cells. Similarly, we determined cytotoxic CD8+
T cells that are subdivided into three categories based on IL-2, IFN-g and TNF production. We have
also included the CD44 marker to be able to distinguish activated CD44hiCD4+ and CD44hiCD8+
T cells. These CD44hi cells can be submitted to a similar gating strategy for cytokine expression
(Figure 6).
Note: Stimulation of T cells with PMA/ionomycin (for 4 h) can cause some downregulation of
surface CD3 and CD4 expression, which can complicate the gating of CD3+ and CD4+ T cells.
However, this problem can be solved by using the negative control (only BFA-treated spleno-
cytes) to set the required gates.
LIMITATIONS
This protocol provides the basics to study thymic, splenic, and circulating T cells in mice. The protocol
can also be used to analyze T cell activation, Treg functionality, and cytokine production of T cells from
lymph nodes. To obtain single-cell suspensions of these lymph nodes, one can use the isolation protocol
for thymus, but for the last step one has to adjust the volume of T cell culture medium according to the
number of lymph nodes. However, the protocol has not been optimized for the analysis of T cells in non-
lymphoid tissues, which requires a more labor-intensive method to isolate immune cells, such as enzy-
matic digestion of the tissue and density gradient centrifugation.
Though this is a very comprehensive protocol concerning T cells, it does not provide any data
concerning the early stages of thymocyte development. Early stages of thymocyte development16 STAR Protocols 2, 100351, March 19, 2021
Figure 4. Gating strategy for T cell activation and Treg cells in blood
CD4+ and CD8+ naive (CD44CD62L+), TEM (CD44+CD62L) and TCM (CD44+CD62L+) cells and Treg cells (FoxP3+CD4+). Smooth pseudocolor plots
are used to facilitate the gating.
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OPEN ACCESSProtocolare well defined by the surface expression of CD44 and CD25 on CD4CD8 T cells. Therefore,
the inclusion of Alexa Fluor 700-conjugated anti-CD44 and BUV395-conjugated anti-CD25 an-
tibodies in the thymocyte flow panel (see Table 2) would solve this issue. In addition, the pres-
ence of CD25 in this panel would allow for the separation of mature CD25+FoxP3+ Tregs from
CD25+ Treg and FoxP3lo Treg progenitors in the thymus (Owen et al., 2019). Furthermore, the
protocol does not provide any information regarding follicular T helper cells and gd-T cells in
mouse spleen.STAR Protocols 2, 100351, March 19, 2021 17
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Figure 5. Gating strategy for cytokine production by T cells
Activated CD4+ and CD8+ T cells are indicated by their CD44 expression. CD4+ T cells expressing IL-2, IL-4, IL-17, IFN-g, and TNF. CD8+ T cells
expressing IL-2, IFN-g, and TNF.
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OPEN ACCESSProtocolFor a more comprehensive analysis of circulating and peripheral immune cells using flow cytometry,
we recommend referring to "Guidelines for the use of flow cytometry and cell sorting in immunolog-
ical studies (second edition)" (Cossarizza et al., 2019).
TROUBLESHOOTING
Problem 1
Contamination of blood single-cell suspensions with red blood cells after ACK lysis step.
Potential solution
The potential reason for this problem might be that the ACK lysis buffer was not effective enough. A
second ACK lysis step can be included in which the pellet is dissolved in 3 mL of ACK lysis buffer for
3 min and the other steps of the protocol are repeated. However, fixation of samples with fixation
buffers provided with the intracellular staining sets should overcome this problem.
Problem 2
Small numbers of PMA/Ionomycin/BFA-stimulated cells after transfer of cells from the 48-well flat-
bottom culture plate to the 96-well polypropylene v-bottom plate.
Potential solution
The potential reason for this problem is the sticking of stimulated cells to the bottom of the 48-well
flat-bottom culture plate. Therefore, take the time to loosen all cells by pipetting up and down in a
clockwise fashion. After cell transfer, one can inspect the plate to see if cells still remain in the culture
plate. If this is the case, add 200 ml 13 D-PBS to the wells and start detaching the cells in the same
fashion as before. These cells can then be added to the pellet obtained after the first centrifugation
step and then the subsequent steps of the protocol can be followed.
Problem 3
No positive staining of some extracellular markers by flow cytometry.
Potential solution
Several reasons may result in this problem.
1) antibody was not added. Ensure adding all the antibodies to the antibody mixes the next time you
repeat the experiment; 2) use of a different antibody clone. Using a different antibody clone than the
one indicated in our protocol may lead to incompatibility with the fixation step. Therefore, we
recommend using the antibody clones mentioned in our protocol. However, if you want to use
another clone, please check clone’s compatibility with fixation buffer in one of the following links:
https://www.thermofisher.com/be/en/home/life-science/cell-analysis/cell-analysis-learning-cen
ter/cell-analysis-resource-library/ebioscience-resources/antibody-fixation-considerations.html
and https://www.biolegend.com/en-us/fixation; 3) inappropriate PMT voltages. The use of un-
stained and single-stained cell controls will help to detect the appropriate PMT voltages and over-
come this problem; 4) do a titration of the antibody.
Problem 4
Weak or undetectable intracellular staining of cytokines in PMA/ionomycin/BFA-treated cells.
Potential solution
There are several possible reasons for this problem.STAR Protocols 2, 100351, March 19, 2021 19
Figure 6. Gating strategy for cytokine production by activated T cells
Activated CD44hiCD4+ and CD44hiCD8+ T cells expressing IL-2, IL-4, IL-17, IFN-g, and TNF.
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OPEN ACCESSProtocol1) not adding BFA in the PMA/ionomycin mix. Ensure that you add BFA in the stimulation mix and
perform a new experiment; 2) lower efficiency of BFA due to repeated freeze/thaw of BFA, which
can affect its inhibitory efficiency. Avoid using BFA aliquots that have been subjected to freeze/
thaw for more than three times; 3) insufficient production of cytokines by PMA/ionomycin/BFA-
stimulated cells. To overcome this problem, culture the PMA/ionomycin/BFA-stimulated cells
for 6 h instead of 4 h. Be aware that culturing cells with BFA for more than 24 h can negatively
influence the cell viability; 4) insufficient binding of fluorophore-conjugated anti-cytokine anti-
bodies with their targets, due to the accidental use of the 13 Permeabilization buffer of the
FoxP3/Transcription Factor Staining Buffer. Ensure that the fixation, the permeabilization and
the intracellular cytokine staining of cells are performed using reagents of the BD Cytofix/Cyto-
perm Fixation/Permeabilization Kit.Problem 5
Undetectable intracellular FoxP3 expression in CD4+ T cells.Potential solution
The following reason might cause this problem.
Insufficient binding of the anti-FoxP3 antibody to its nuclear target due to the accidental use of the
BD Cytofix/Cytoperm Fixation/Permeabilization Kit instead of the FoxP3/Transcription Factor Stain-
ing Buffer Set during the intracellular staining procedure. In this case, the nucleus will remain intact
and the anti-FoxP3 antibody will not bind to FoxP3. To solve this problem, ensure that you always
use the fixation and permeabilization buffers of the FoxP3/Transcription Factor Staining Buffer Set
during the intracellular FoxP3 detection.RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact, Rudi Beyaert (rudi.beyaert@irc.vib-ugent.be).Materials availability
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